Morning Briefing
Summaries of health policy coverage from major news organizations
Perspectives: Texas Judge's Upcoming Ruling On Mifepristone Not As Dire As It May Seem
Despite the barrage of predictions that this case could ban mifepristone and take it off the market, there are several basic legal principles suggesting that Judge Kacsmaryk鈥檚 power is limited and that a ruling for the plaintiffs will not necessarily change much at all with medication abortion. (David S. Cohen, Greer Donley and Rachel Rebouche, 2/28)
As a Texas federal judge mulls whether to halt the Food and Drug Administration鈥檚 longstanding approval of an abortion pill, 12 liberal states have filed a separate lawsuit in a federal district court in Washington State that seeks to force the FDA to drop some restrictions on the drug. (Noah Feldman, 2/28)
Also 鈥
In this episode of 鈥淚ntention to Treat,鈥 a study participant and a long-time investigator of hallucinogenic drugs for psychiatric conditions illuminate the effects of psilocybin in patients with depression. (2/23)
Access to pharmaceutical products and health care services should be sustainable for everyone, regardless of where they live, and sustainability efforts should focus on long-term investment in creating health equity. (Jayasree K. Iyer and Pat Garcia-Gonzalez, 2/28)
Pfizer Inc. is reportedly working on a deal that could finally satisfy investors鈥 cravings for a big acquisition. Last night, the Wall Street Journal reported that the pharma company is in very early talks to acquire Seagen Inc. for more than $30 billion, a deal that would instantly add four approved cancer drugs to its portfolio. 聽(Lisa Jarvis, 2/27)